Results 41 to 50 of about 5,389 (186)

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma [PDF]

, 2022
Despite the significant progress in the treatment of unresectable or metastatic BRAF V600-mutant melanoma, there remains two primary treatment options: targeted therapy and immunotherapy.
Ascierto, Paolo A, Brill, Kimberli, Dummer, Reinhard, McKean, Meredith, Panella, Timothy, Pietro, Alessandra di, Polli, Anna, Ribas, Antoni, Robert, Caroline, Santos, Edgardo S, Schadendorf, Dirk, Sullivan, Ryan J   +11 more
core   +1 more source

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies

Molecules, 2023
The altered activation or overexpression of protein kinases (PKs) is a major subject of research in oncology and their inhibition using small molecules, protein kinases inhibitors (PKI) is the best available option for the cure of cancer.
George Mihai Nitulescu, Gheorghe Stancov, Oana Cristina Seremet, Georgiana Nitulescu, Dragos Paul Mihai, Cosmina Gabriela Duta-Bratu, Stefania Felicia Barbuceanu, Octavian Tudorel Olaru   +7 more
doaj   +1 more source

MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma [PDF]

, 2017
The mitogen-activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E-mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion of serine
Dang, Kien X., Haglund, Caj, Ho, Tho H., Koistinen, Hannu, Lintula, Susanna, Mustonen, Harri, Räsänen, Kati, Stenman, Jakob, Stenman, Ulf-Håkan   +8 more
core   +1 more source

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study [PDF]

, 2021
Adverse events; Cetuximab; EncorafenibEventos adversos; Cetuximab; EncorafenibEsdeveniments adversos; Cetuximab; EncorafenibColorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with ...
Grothey, Axel, Tabernero Caturla, Josep, Trevino, T. L., Van Cutsem, Eric, Velez, L, Yaeger, Rona   +5 more
core   +1 more source

Frontiers in Pigment Cell and Melanoma Research

, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca, Bosenberg, Marcus W., Box, Neil F., Brash, Douglas, Cassidy, Pamela B., Chen, Suzie, D'Orazio, John August, Filipp, Fabian V., Fujita, Mayumi, Goh, Boon-Kee, Herlyn, Meenhard, Indra, Arup K., Larue, Lionel, Leachman, Sancy A., Liu-Smith, Feng, Manga, Prashiela, Montoliu, Lluis, Norris, David A., Poole, Caroline Le, Shellman, Yiqun, Smalley, Keiran S. M., Spritz, Richard A., Sturm, Richard A., Swetter, Susan M., Terzian, Tamara, Wakamatsu, Kazumasa, Weber, Jeffrey S.   +26 more
core   +1 more source

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib

Case Reports in Oncological Medicine, 2019
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver
Nicholas Gravbrot, Srinath Sundararajan
doaj   +1 more source

Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer [PDF]

, 2023
PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with METHODS: In this ongoing, open-label, single-arm, phase II study, patients ...
et al.,, Morgensztern, Daniel, Riely, Gregory J   +2 more
core   +2 more sources

Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors

Frontiers in Oncology, 2023
IntroductionCombination molecular BRAF/MEK inhibitors targeted therapy has been shown to improve overall survival in patients with BRAF V600 mutated unresectable or metastatic melanoma.
Charlotte Bonnefin, Fanny Duval, Marie Rouanet, Marie Kostine, Marie Kostine, Emilie Gerard   +5 more
doaj   +1 more source

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

Frontiers in Pharmacology
ObjectiveTo investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).MethodsReports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004–2023q3) were ...
Shuang Xia, Shuang Xia, Shuang Xia, Jing-Wen Xu, Kang-Xin Yan, Yoshihiro Noguchi, Mayur Sarangdhar, Mayur Sarangdhar, Mayur Sarangdhar, Miao Yan, Miao Yan, Miao Yan   +11 more
doaj   +1 more source

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial [PDF]

, 2023
PURPOSE In COLUMBUS part 1, patients with advanced BRAF$^{V600}$-mutant melanoma were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice a day (COMBO450), vemurafenib 960 mg twice a day, or encorafenib 300 mg once daily
Arance, Ana, Ascierto, Paolo A, Chiarion-Sileni, Vanna, de Groot, Jan Willem B, Dummer, Reinhard, Dutriaux, Caroline, Flaherty, Keith T, Garbe, Claus, Gogas, Helen J, Gutzmer, Ralf, Krajsova, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandala, Mario, Robert, Caroline, Schadendorf, Dirk, Yamazaki, Naoya   +16 more
core   +1 more source